Literature DB >> 6352971

Landmark article, June 19, 1915. The isolation in crystalline form of the compound containing iodin, which occurs in the thyroid. Its chemical nature and physiologic activity. By E.C. Kendall.

E C Kendall.   

Abstract

By an alkaline alcoholic hydrolysis, the thyroid proteins are broken into many simpler constituents. These may be separated into two groups: the acid insoluble compounds are designated Group A; those acid soluble, Group B. From Group A a pure crystalline compound, containing 60 per cent of iodin, has been isolated. It appears to be di-iodo-di-hydroxy-indol. Group B contains iodin in some unknown form of combination. It is a mixture containing amino-acid complexes and a low molecular weight. Administration of A produces in the dog and in the human being a rapid increase in pulse rate and vigor, and increase in metabolism and nervous irritability. This physiologic activity is produced by the compound containing iodin in all stages of purity up to and including its crystalline form. Given in excess, toxic symptoms are produced. The amount of the iodin compound required to produce toxic effects is exceedingly small. In exophthalmic goiter two abnormal conditions exist. First, the secreting capacity of the gland is greatly increased and, second, the reservoir capacity of the gland is greatly decreased. The iodin compound plays an important role in the production of the symptoms of exophthalmic goiter. The constituents of Group B produce no toxic symptoms, but in cases of cretinism, myxedema and certain skin conditions, they exert physiologic activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352971

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

1.  Highlights in thyroidology: a historical vignette.

Authors:  Michael Weissel
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

2.  The discovery of thyroid replacement therapy. Part 3: A complete transformation.

Authors:  Stefan Slater
Journal:  J R Soc Med       Date:  2011-03       Impact factor: 5.344

3.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

4. 

Authors:  B Romeis
Journal:  Wilhelm Roux Arch Entwickl Mech Org       Date:  1925-11

5.  Treatment of hypothyroidism: all that glitters is gold?

Authors:  Anna Maria Formenti; Gherardo Mazziotti; Raffaele Giubbini; Andrea Giustina
Journal:  Endocrine       Date:  2016-02-29       Impact factor: 3.633

Review 6.  Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism.

Authors:  Wilmar M Wiersinga
Journal:  Nat Rev Endocrinol       Date:  2014-01-14       Impact factor: 43.330

Review 7.  The emergence of levothyroxine as a treatment for hypothyroidism.

Authors:  James V Hennessey
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

Review 8.  Thyroid hormone misuse and abuse.

Authors:  Victor J Bernet
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

Review 9.  Nuclear hormone receptors put immunity on sterols.

Authors:  Fabio R Santori
Journal:  Eur J Immunol       Date:  2015-08-27       Impact factor: 5.532

10.  Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  J Thyroid Res       Date:  2011-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.